Literature DB >> 29629901

Blocking immune intrusion into the brain suppresses epilepsy in Rasmussen's encephalitis model.

Lawrence Steinman.   

Abstract

Rasmussen's encephalitis (RE) is a neuroinflammatory disease that typically affects only one hemisphere of the brain, resulting in severe seizures. Sixty years after the disease was first described, the preferred and best treatment option for RE is grotesque and involves removing a hemisphere of the brain (hemispherectomy); therefore, a better understanding of this seizure disorder may provide additional, less invasive therapeutic options. In this issue of the JCI, Carmant and colleagues have developed an animal model of this focal seizure disorder. The model provides experimental insights into the pathogenesis of RE and potential new treatments for this disease.

Entities:  

Mesh:

Year:  2018        PMID: 29629901      PMCID: PMC5919819          DOI: 10.1172/JCI120444

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  16 in total

1.  Focal seizures due to chronic localized encephalitis.

Authors:  T RASMUSSEN; J OLSZEWSKI; D LLOYDSMITH
Journal:  Neurology       Date:  1958-06       Impact factor: 9.910

Review 2.  Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.

Authors:  Sophia Varadkar; Christian G Bien; Carol A Kruse; Frances E Jensen; Jan Bauer; Carlos A Pardo; Angela Vincent; Gary W Mathern; J Helen Cross
Journal:  Lancet Neurol       Date:  2014-02       Impact factor: 44.182

3.  Use of immunoglobulins in the prevention of GvHD in a xenogeneic NOD/SCID/γc- mouse model.

Authors:  J Gregoire-Gauthier; L Durrieu; A Duval; F Fontaine; M M Dieng; M Bourgey; N Patey-Mariaud de Serre; I Louis; E Haddad
Journal:  Bone Marrow Transplant       Date:  2011-05-16       Impact factor: 5.483

Review 4.  Humanized mice for immune system investigation: progress, promise and challenges.

Authors:  Leonard D Shultz; Michael A Brehm; J Victor Garcia-Martinez; Dale L Greiner
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

Review 5.  Autoimmune disease.

Authors:  L Steinman
Journal:  Sci Am       Date:  1993-09       Impact factor: 2.142

6.  Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models.

Authors:  Bahareh Ajami; Nikolay Samusik; Peter Wieghofer; Peggy P Ho; Andrea Crotti; Zach Bjornson; Marco Prinz; Wendy J Fantl; Garry P Nolan; Lawrence Steinman
Journal:  Nat Neurosci       Date:  2018-03-05       Impact factor: 24.884

7.  GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis.

Authors:  H Wiendl; C G Bien; P Bernasconi; B Fleckenstein; C E Elger; J Dichgans; R Mantegazza; A Melms
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

8.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

Review 9.  Treatment of Rasmussen encephalitis half a century after its initial description: promising prospects and a dilemma.

Authors:  Christian G Bien; Johannes Schramm
Journal:  Epilepsy Res       Date:  2009-07-16       Impact factor: 3.045

Review 10.  Natalizumab: bench to bedside and beyond.

Authors:  Richard Rudick; Chris Polman; David Clifford; David Miller; Lawrence Steinman
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

View more
  2 in total

1.  PET/CT imaging of CSF1R in a mouse model of tuberculosis.

Authors:  Catherine A Foss; Alvaro A Ordonez; Ravi Naik; Deepankar Das; Andrew Hall; Yunkou Wu; Robert F Dannals; Sanjay K Jain; Martin G Pomper; Andrew G Horti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-17       Impact factor: 10.057

Review 2.  Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases.

Authors:  Heinz Wiendl; Catharina C Gross; Jan Bauer; Doron Merkler; Alexandre Prat; Roland Liblau
Journal:  Nat Rev Neurol       Date:  2021-05-28       Impact factor: 42.937

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.